TGFB1 and leukemia: Overall, the intimate cross-talk between leukemia and MSCs, resulting in in vitro TGFβ signaling alterations, suggests the cruciality of further in vivo studies about the impact of TGFβ targeting agents on leukemia progression and response to therapy.